New treatments look to ambush the old in some of pharma's key drug classes

It has been a whirlwind of a year for pharma, with pricing battles, regulatory showdowns and all-but-legendary M&A. But on the ground, it's Rock-em-Sock-em Robots in some of the industry's biggest markets. A steady flow of new drugs in 2014--and a slate of anticipated launches in 2015--have established brands defending their titles and newcomers looking to land a gut-punch or two, if not a knockout. Check out FiercePharma's match-ups to watch in the coming year. Report

Suggested Articles

Novartis said it plans to use the complete response rate data for a U.S. filing in follicular lymphoma in 2021.

Amarin's wild 2020 ride continues with plans to launch its cardiovascular med Vascepa in Europe without a bigger marketing partner.

The CD19 antibody, used in tandem with Celgene's Revlimid, represents the first FDA approval in second-line diffuse large B-cell lymphoma.